Kaplan Fox Investigation Raises Securities Risk for Cellebrite (CLBT)
Aug 21, 2026, 11:14 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Legal investigations into securities violations can create immediate uncertainty and attract attention from regulators and plaintiffs, often pressuring stock during uncertainty. While no formal action is announced, the timing after an ARR miss and leadership change amplifies risk; prior stock reaction (29% drop after Q2 news) demonstrates potential for outsized moves on related headlines.
AI summary
What happened, with direct paths to the underlying reporting
Kaplan Fox & Kilsheimer LLP disclosed an investigation into potential securities violations involving Cellebrite (CLBT) after the Q2 results. Cellebrite reported ARR of $507.8M, missing guidance and trimming ARR by about $15M, while appointing a new CEO, Shiv Ramji. The disclosure could heighten investor scrutiny and add to near-term volatility in CLBT shares.
Kaplan Fox launches securities investigation into Cellebrite (CLBT). Investors should monitor potential legal risks.
Full-year ARR guidance cut by about $15M at the midpoint.
CEO Tom Hogan replaced by Shiv Ramji effective immediately.
Stock falls 29% to $10.80 on Aug 13, 2026.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
- Cellebrite DI Ltd. beat earnings estimates with $0.08 per share, a 33.33% surprise. - Revenues for the quarter reached $89.58 million, exceeding estimates by 4.15%. - Recent sto…
